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Conclusions: The subtraction method described here validates the x-
ray markers as an accurate surrogate for the HDR brachytherapy 
source position. These markers were then appropriate references for 
validation of the algorithm used to determine source position in a two 
dimensional plane parallel to the imaging panel, as derived using an 
EPID based delivery validation system described elsewhere at this 
meeting. EPID measurements of source position were confirmed to be 
accurate within ± 1 mm at source-detector distances up to 200 mm. 
 
 POSTER DISCUSSION: 5: PREVENT: EFFECTS OF 
RADIOTHERAPY ON NORMAL TISSUE  
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Purpose/Objective: Prostate cancer patients treated with 
neoadjuvant androgen ablation experience less radiation-induced 
intestinal toxicity. This can be due to the size reduction of bulky 
prostatic tumours and optimization of the target volume. The aim of 
this study was to evaluate if leuprorelin exerts itself a protective 
effect on irradiated bowel. 
Materials and Methods: C57BL/6J mice underwent 12Gy total body 
irradiation (TBI), with or without a monthly i.p. injection of 
leuprorelin (enantone®, 0.054 mg/Kg), started three months before 
TBI. Mice were sacrificed 24 or 72h after TBI and small bowel 
(jejunum, ileum) segments were collected for histological and 
molecular analysis. 
Microcolony survival assay was also performed, to evaluate radiation-
induced damage on crypts and the potential protective effect of 
leuprorelin. Radioprotection was correlated with crypt regeneration; 
crypts containing at least 10 viable cells were considered regenerating 
crypts.  
Results: At hematoxylin eosin staining, untreated controls showed 
normal jejunal wall features,with long villi and well developed tubular 
glands. Irradiation caused a time-dependent reduction of the tubular 
glands and occurrence of a marked inflammatory infiltrate. euprorelin 
pre-treatment appeared to blunt the radiation-induced changes: the 
columnar epithelium mostly showed normal features, with continuous 
striated border and intercalated goblet cells; the inflammatory 
infiltrate in the mucosal/submucosal stroma was markedly reduced in 
comparison with the irradiated mice. 
Real-Time RT-PCR analysis showed that leuprorelin significantly 
decreased radiation-induced collagen type I and type III, TGFbeta, 
Mmp2, Mmp13 and p53 gene expression in the jejunum of treated 
mice. 
Leuprorelin pre-treatment was also able to inhibit TGFbeta and p-
NFkB protein expression induced by irradiation in the jejunum, as 
revealed by western blot analysis. 
Pre-irradiation administration of leuprorelin significantly increased 
the number of regenerating crypts in the jejunum, as compared to 
mice undergone irradiation alone.  
Conclusions: Pretreatment with leuprorelin exerts a protective effect 
against radiation-induced intestinal injury in mice. These findings 
confirm clinical observations in irradiated prostate cancer patients 
and suggest that prostate size reduction is not the only mechanism at 
the basis of better intestinal tolerance after neoadjuvant androgen 
ablation. More investigations are needed to establish a possible way of 
action for the reported effect of leuprorelin on irradiated intestinal 
mucosa  
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Purpose/Objective: The introduction of flattening filter free (FFF) 
photon beams to deliver higher instantaneous dose rates and 
shortened overall treatment times, re-introduced controversy about 
the biological consequences of these high dose rates. We hypothesize 
that high dose rate irradiation will decrease cell survival in normal 
and cancer cell lines and even more in cancer cells deficient for 
homologous recombination. Additionally, we hypothesize that removal 
of the flattening filter will result in an enhanced relative biological 
effectiveness (RBE), independently of the dose rate. 
Materials and Methods: Human breast adenocarcinoma (MCF7), 
colorectal adenocarcinoma (HCT116 and DLD1), glioblastoma (U373 
and U87) and non small cell lung adenocarcinoma (A549) cells were 
irradiated in the range 0 - 10 Gy. Additionally, DNA repair deficient 
HCT116 (DNA-PKcs-/-, NHEJ deficient) or DLD1 (BRCA2-/-, HR 
deficient) and normal breast (MCF10A) and lung bronchial (NL20) 
epithelial cell lines were exposed to similar dose schedules. To 
investigate the effect of high dose rate irradiation, clonogenic survival 
was assessed after exposing cells to 4 or 24 Gy/min FFF using a Varian 
TrueBeam accelerator (10 MV). Additionally, to investigate the effect 
of flattening filter removal on cell survival, cells were exposed to 4 
Gy/min with or without flattening filter. RBE estimations were 
performed comparing the different photon spectra of FF and FFF 
beams. 
Results: Cell survival in tumor or normal tissue cell lines was not 
influenced by high dose rate irradiation. The survival curves for A549 
non small cell lung cancer cells are shown as an example. Although 
DNA repair deficient cell lines showed an increased radiosensitivity, 
high dose rate irradiation did not influence survival. Furthermore, RBE 
was not significantly different from unity in any of the cell lines 
between FFF and conventional flattened beams. 
 
 
Conclusions: High dose rate irradiation did not affect long term cell 
survival and DNA repair for human cancer and normal cell lines of 
different origin. These results suggest that high dose rate does not 
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influence treatment outcome or treatment toxicity. Furthermore, no 
enhanced RBE was found for FFF compared to FF photon beams. 
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Purpose/Objective: Radiotherapy to collateral structures such as the 
carotid artery leads to atherosclerosis and increased stroke risk. 
Arterial thickening is a precursor to atherosclerosis. Carotid intima-
medial thickness (CIMT), a measure of arterial thickening, is a 
validated surrogate for prediction of cardio- and cerebrovascular 
events. Its application in irradiated arteries as a measure of 
accelerated atherosclerosis has shown variable results. This study 
investigates CIMT as an early marker of radiation-induced damage in 
head and neck cancer patients. 
Materials and Methods: Patients with head and neck cancer treated 
with a wedged-pair and matched neck technique or hemi-neck 
radiotherapy (unirradiated (unirr) side as control) at least 2 years 
previously were included. Patients had been prescribed a dose of at 
least 50 Gy to the neck. CIMT was measured on B-mode ultrasound 
using semi-automated detection software. Measurements were taken 
from the far wall in 4 arterial segments: proximal- (prox), mid-, distal 
(dist) common carotid artery (CCA), and bifurcation and were 
compared to corresponding segments in the unirr artery. CIMT 
measurements >75th percentile of a reference normal population were 
considered abnormal and at increased cardiovascular risk. 
Results: 24 patients (16 males) with a median age of 58 yrs 
(interquartile range (IQR) 49.2 – 64.2) were included. The mean 
maximum dose to the irradiated (irr) artery was 61.2 Gy (IQR 52.6 – 
61.8) and 1.1 Gy (IQR 1.0 – 1.8 Gy) to the unirr carotid artery. Mean 
CIMT was significantly greater in irr carotid arteries compared to unirr 
arteries: mid-CCA (0.75mm ± 0.2 (irr) vs 0.64mm ± 0.12 (unirr) (P = 
0.0057), distal CCA (0.79mm ± 0.24 (irr) vs 0.64mm ± 0.14 (unirr) (P = 
0.005), and bifurcation (0.85mm ± 0.28 (irr) vs 0.7mm ± 0.17 (unirr) (P 
= 0.0231). For the irr prox CCA, 23/24 (95.8%) had a CIMT > 75th 
percentile vs 16/24 (66.7%) for unirr prox CCA. For irr mid CCA, 20/24 
(83.3%) had CIMT >75th percentile vs 15/24 (62.5%) for unirr mid CCA. 
21/24 (87.5%) of irr dist CCA CIMT was >75th percentile vs 11/24 (45.8) 
for unirr dist CCA. For irr bifurcation, 15/21 (71.4%) had a CIMT >75th 
percentile vs 11.24 (45.8%) for unirr bifurcation. 
Conclusions: CIMT is increased in irr carotid arteries, suggesting this 
may be a useful marker of radiation-induced carotid atherosclerosis. 
The proximal CCA appears to be less sensitive to radiation-induced 
damage. 
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Purpose/Objective: This is the first report on the application and 
outcomes of hyperbaricoxygen therapy (HBO) for late adverse events 
which developed after proton or carbon-ionbeam radiation therapy. 
Materials and Methods: Between April 2008 and May 2012, 40 patients 
underwent HBO for late adverse events (105 episodes of 8 events) 
which developed more than 5 months after particle radiotherapy. 
There were 24 male and 16 female patients aged 15-83 years (median: 
67 years), and the performance state (PS) at the initiation of HBO 
was: PS0:PS1:PS2:PS3= 0:24:13:3. The primary diseases treated with 
particle radiotherapy were head-and-neck tumor in 23 patients, 
prostate cancer in 8, bone soft tissue tumor in 5, liver cancer in 4, 
and lung metastasis in 1. The late adverse events treated with HBO 
were classified into 8 events using CTC-AEver. 4.0. HBO was 
performed 3 times or more weekly, as a rule. The HBO chamber was 
compressed with 100% oxygen to 2.0 ATA inside, and the duration of 
treatment (pressure-keeping time) was 60 minutes. Responder of HBO 
was defined as a case of improvement in CTC-AE score. 
 
 
Results:  
  
HBO was initiated 5-64 months (median: 19 months) after particle 
radiotherapy. The total number of HBO was 4-120 (median: 29). Table 
shows grading score of late adverse events before and after HBO. 
Response rate (number of responder/total cases) of 8 events was: 
hematuria, 100% (4/4); rectal bleeding, 67% (4/6); pain, 56% (18/32); 
central nervous necrosis, 50% (2/4); mucosalulcer or fistula, 36% 
(8/22); mandibular bone necrosis, 28% (5/18); trismus, 15% (2/13); 
and skin ulcer, 0% (0/9). Total response rate was 40% (43/105). The 
average number of HBO was significantly higher in responder 
(69±48.9) than in non-responder (44±27.9) groups (p=.001). Adverse 
events due to ABO were minimal. Otitis media (non-infectious) 
occurred in 14 patients (35%) (Grade 1in 12 (30%), Grade 2 in 1 (2.5%) 
and Grade3 in 1 (2.5%)). TIA, diarrhea, bronchitis, cerebral infarction 
and sinusitis occurred in each one patient, however these events were 
transient and HBO did not be discontinued. 
Conclusions: HBO was effective for late radiation disorders after 
particle radiotherapy especially in hematuria, rectal bleeding, pain, 
and central nervous necrosis. Total response rate was 40% (43/105). It 
was suggested that many times (69±48.9) applications of HBO are 
necessary to obtain an effect.  
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Purpose/Objective: Numerous studies investigate the normal tissue 
dose-response relation. However, limited numbers of patients per 
study and the low incidence of toxicities render the relation 
uncertain. The aim of this study is to apply a statistical bootstrap 
analysis to evaluate the uncertainty in the predicted dose-response 
due to sampling variability. 
Materials and Methods: Two clinical endpoints were considered: 
myelopathy of the cervical spinal cord and pneumonitis. Data was 
taken from the recently published QUANTEC review. In order to 
evaluate the uncertainty in the clinical data, a Monte Carlo-based 
bootstrap analysis was applied. Ten thousand bootstrap replicates of 
the original dataset were produced by random sampling with 
replacement. This simulates alternative outcomes at each dose in a 
different sample of patients of the same size from the same 
population. The analysis requires only the dose, the number of 
patients, and the number of occurrences of the studied endpoint. The 
dose reported in the QUANTEC review was used: the equivalent dose 
given in 2-Gy fractions (EQD2) for the spinal cord, and the mean dose 
for the lung. Two dose-response models, a Poisson-based model and 
the Lyman model, were fitted to each bootstrap replicate using 
maximum likelihood. 
Results: The bootstrap analysis generates a family of curves 
representing the range of plausible dose-response relations. The 95% 
confidence intervals of the curve families for the two models overlap 
for doses included in the clinical study, but diverge beyond that. For 
higher doses, the Lyman model indicates a steeper slope than does 
the Poisson-based model. The bootstrap distributions of the model 
parameters D50 and y (m) indicate negative (positive) correlation. For 
both data sets, the likelihood of the observed data was higher for the 
Lyman model. This result was robust over the bootstrap analysis with 
higher likelihood of the Lyman model for over 90% of the bootstrap 
replicates, in both data sets. 
